Immunotherapy Updates in Advanced Hepatocellular Carcinoma.
CTLA-4
PD-1
PD-L1
chimeric antigen receptor
hepatocellular carcinoma
immune checkpoint inhibitors
immunotherapy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
30 Apr 2021
30 Apr 2021
Historique:
received:
16
04
2021
accepted:
26
04
2021
entrez:
5
5
2021
pubmed:
6
5
2021
medline:
6
5
2021
Statut:
epublish
Résumé
Hepatocellular carcinoma (HCC) is the second most common cause of cancer death worldwide. HCC tumor development and treatment resistance are impacted by changes in the microenvironment of the hepatic immune system. Immunotherapy has the potential to improve response rates by overcoming immune tolerance mechanisms and strengthening anti-tumor activity in the tumor microenvironment. In this review, we characterize the impact of immunotherapy on outcomes of advanced HCC, as well as the active clinical trials evaluating novel combination immunotherapy strategies. In particular, we discuss the efficacy of atezolizumab and bevacizumab as demonstrated in the IMbrave150 study, which created a new standard of care for the front-line treatment of advanced HCC. However, there are multiple ongoing trials that may present additional front-line treatment options depending on their efficacy/toxicity results. Furthermore, the preliminary data on the application of chimeric antigen receptor (CAR-T) cell therapy for treatment of HCC suggests this may be a promising option for the future of advanced HCC treatment.
Identifiants
pubmed: 33946408
pii: cancers13092164
doi: 10.3390/cancers13092164
pmc: PMC8125389
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
J Hepatol. 2020 Dec;73(6):1460-1469
pubmed: 32710922
J Clin Oncol. 2020 Jan 20;38(3):193-202
pubmed: 31790344
Gastroenterology. 2007 Jun;132(7):2328-39
pubmed: 17570208
Drugs. 2020 Oct;80(15):1587-1594
pubmed: 32990939
J Surg Oncol. 2016 Jan;113(1):55-61
pubmed: 26661118
Onco Targets Ther. 2016 Mar 23;9:1767-76
pubmed: 27042127
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Nature. 2006 Feb 9;439(7077):682-7
pubmed: 16382236
Future Oncol. 2020 May;16(15):975-989
pubmed: 32352320
Hepatobiliary Pancreat Dis Int. 2018 Aug;17(4):301-309
pubmed: 29861325
Front Immunol. 2018 Oct 29;9:2493
pubmed: 30420856
Clin Cancer Res. 2009 Feb 1;15(3):971-9
pubmed: 19188168
Immunotherapy. 2016;8(3):299-313
pubmed: 26865127
J Autoimmun. 2016 Jan;66:60-75
pubmed: 26358406
Gene Expr. 2020 Jun 12;20(1):53-65
pubmed: 32340652
J Hepatol. 2020 Feb;72(2):320-341
pubmed: 31954495
Int J Cancer. 2011 Feb 15;128(4):887-96
pubmed: 20473887
Lancet. 2017 Jun 24;389(10088):2492-2502
pubmed: 28434648
Nat Rev Cancer. 2015 Aug;15(8):457-72
pubmed: 26205340
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Front Oncol. 2018 Jul 13;8:269
pubmed: 30057891
Onco Targets Ther. 2020 Nov 16;13:11725-11740
pubmed: 33235462
Lancet Oncol. 2018 Jul;19(7):940-952
pubmed: 29875066
Semin Cancer Biol. 2021 Feb 2;:
pubmed: 33545339
Clin Cancer Res. 2017 Jan 15;23(2):478-488
pubmed: 27535982
Immunol Lett. 2013 Feb;150(1-2):116-22
pubmed: 23261718
Cancer Microenviron. 2015 Apr;8(1):15-21
pubmed: 25326055
J Hepatol. 2017 Mar;66(3):545-551
pubmed: 27816492
Cancer Res. 2009 Jul 1;69(13):5514-21
pubmed: 19549903
Front Oncol. 2020 Dec 14;10:605380
pubmed: 33381459
Nat Immunol. 2013 Oct;14(10):996-1006
pubmed: 24048121
Scand J Immunol. 2017 Mar;85(3):175-181
pubmed: 28109025
Molecules. 2020 Dec 22;26(1):
pubmed: 33374953
J Immunol. 2007 Mar 1;178(5):2714-20
pubmed: 17312113
Sci Rep. 2017 Jul 17;7(1):5532
pubmed: 28717238
Front Immunol. 2018 May 03;9:978
pubmed: 29774034
J Natl Compr Canc Netw. 2020 Mar;18(3):230-241
pubmed: 32135517
Pharmacol Ther. 2018 Jan;181:49-75
pubmed: 28723416
Cancer Immunol Res. 2014 May;2(5):393-8
pubmed: 24795351
Pharmacol Ther. 2016 Oct;166:30-9
pubmed: 27373504
Biochim Biophys Acta. 2000 Jul 14;1480(1-2):41-56
pubmed: 11004554
Annu Rev Immunol. 2001;19:565-94
pubmed: 11244047
ESMO Open. 2019 Jan 24;4(1):e000442
pubmed: 30792906
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
Hepatology. 2020 Apr;71(4):1247-1261
pubmed: 31378984
World J Gastroenterol. 2016 Jan 7;22(1):275-83
pubmed: 26755876
J Exp Med. 2003 Jul 7;198(1):39-50
pubmed: 12847136
World J Gastroenterol. 2011 Jul 28;17(28):3322-9
pubmed: 21876620
Clin Cancer Res. 2019 Feb 1;25(3):912-920
pubmed: 30274981
Mod Pathol. 2017 Oct;30(10):1411-1421
pubmed: 28664936
Lancet Oncol. 2020 Jun;21(6):808-820
pubmed: 32502443
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
Immunity. 2018 Apr 17;48(4):812-830.e14
pubmed: 29628290
Cancer Immunol Immunother. 2019 Dec;68(12):2055-2066
pubmed: 31724091
J Immunother Cancer. 2019 Nov 29;7(1):333
pubmed: 31783782
Cancer Treat Rev. 2020 Jun;86:102017
pubmed: 32335505
Int Immunopharmacol. 2020 Dec;89(Pt A):107135
pubmed: 33189609
Front Immunol. 2020 Jun 17;11:1109
pubmed: 32625204
JAMA Oncol. 2020 Nov 1;6(11):e204564
pubmed: 33001135
Cancer Immunol Res. 2019 Sep;7(9):1390-1395
pubmed: 31289040
Cancer Immunol Res. 2017 Apr;5(4):312-318
pubmed: 28246107
J Immunother Cancer. 2020 Dec;8(2):
pubmed: 33335028
Mol Cancer. 2020 Jun 27;19(1):110
pubmed: 32593303
Nat Med. 2020 Nov;26(11):1733-1741
pubmed: 32895571
J Cancer. 2017 Feb 10;8(3):410-416
pubmed: 28261342
PLoS One. 2011;6(9):e23621
pubmed: 21912640
Sci Transl Med. 2020 Mar 25;12(536):
pubmed: 32213632
Drugs. 2017 Aug;77(12):1369-1376
pubmed: 28643244
Cancer Control. 2018 Jan-Dec;25(1):1073274818789361
pubmed: 30032643
J Hepatol. 2013 Jul;59(1):81-8
pubmed: 23466307
Annu Rev Pharmacol Toxicol. 2021 Jan 6;61:805-829
pubmed: 33035447
J Exp Clin Cancer Res. 2019 Jun 13;38(1):255
pubmed: 31196207
J Immunother. 2019 Feb/Mar;42(2):33-42
pubmed: 30586347
Ann Oncol. 2017 Jul 1;28(suppl_4):iv119-iv142
pubmed: 28881921
J Clin Oncol. 2020 Apr 10;38(11):1154-1163
pubmed: 31961766